Cargando…
Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study
BACKGROUND: Up to 37.7% of patients experience symptoms beyond 12 weeks after infection with SARS-CoV-2. To date care for people with long covid has centred around multidisciplinary rehabilitation, self care and self pacing. No pharmacotherapy has been shown to be beneficial. METHODS: In this single...
Autores principales: | O'Kelly, Brendan, Vidal, Louise, McHugh, Tina, Woo, James, Avramovic, Gordana, Lambert, John S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250701/ https://www.ncbi.nlm.nih.gov/pubmed/35814187 http://dx.doi.org/10.1016/j.bbih.2022.100485 |
Ejemplares similares
-
Assessing the impact of COVID-19 at 1-year using the SF-12 questionnaire: Data from the Anticipate longitudinal cohort study
por: O'Kelly, Brendan, et al.
Publicado: (2022) -
HepCare Plus: Enhancing Primary Care Identification and Treatment of Hepatitis C Virus in High-Risk Individuals
por: O’Gorman, Tessa, et al.
Publicado: (2022) -
The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
por: Parchinski, Kaley, et al.
Publicado: (2023) -
The reactivation of herpesviruses in severe COVID-19; a retrospective analysis of a critical care cohort
por: Moynan, David, et al.
Publicado: (2023) -
Anticipate study protocol: Baseline profile and care outcomes of patients attending Mater Misericordiae University Hospital with COVID-19 infection
por: Avramovic, Gordana, et al.
Publicado: (2021)